Abdominal Radiology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 10, 2024
Language: Английский
Siberian Journal of Oncology, Journal Year: 2025, Volume and Issue: 23(6), P. 32 - 40
Published: Jan. 13, 2025
177 Lu-PSMA-617 is a new therapy option for PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC) with proven efficacy. 225 Ac-PCMA-617 an alpha emitter, making this drug potentially more powerful. Despite the active use of Ac-PSMA-617 worldwide, no randomized phase III studies have yet been conducted. The present prospective cohort study presents experience in A.F. Tsyb MRRC. Material and Methods . included mCRPC patients prostate-specific membrane antigen (PSMA) overexpression confirmed by PET-CT or SPECT-CT, who received first course 2023. Results Forty three 1 to 6 (median 2) administrations Ac-PSMA-617, 26 (60 %) these had history therapy, 13 (30 radium chloride [ 223 Ra] 10 (23 chemotherapy. Five (12 liver metastases at time inclusion study. PSA reduction than 50 % was recorded 55 patients, biochemical response significantly frequent PSMA-naïve group, 63 vs 35 %; number adverse events also lower group. But advantage overall survival (OS) revealed time. Favorable prognosis factors therapy; contrast, metastasis negative prognostic factor. found differences OS among taxane-naïve 1–2 lines Continued androgen receptor targeted agents after initiation treatment showed effect on OS. Conclusions may be effective Lu-PCMa resistance, but there are data increase patient when administered as first-line radioligand therapy.
Language: Английский
Citations
0
Journal of Molecular Structure, Journal Year: 2025, Volume and Issue: unknown, P. 142203 - 142203
Published: March 1, 2025
Language: Английский
Citations
0
International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 311, P. 143965 - 143965
Published: May 5, 2025
Language: Английский
Citations
0
The Prostate, Journal Year: 2024, Volume and Issue: 84(12), P. 1119 - 1127
Published: May 15, 2024
The prognosis of metastatic castration-resistant prostate cancer (mCRPC) is influenced by numerous individual factors. Despite various proposed prognostic models, the clinical application these remains limited, probably due to complexity. Our study aimed evaluate predictive value Bellmunt risk score, which well-known for urothelial carcinoma and easily assessed, in mCRPC patients.
Language: Английский
Citations
2
Published: Aug. 25, 2024
Most human cancers are heterogeneous consisting of cancer cells at different epigenetic and transcriptional states with distinct phenotypes, functions, drug sensitivities. This inherent cell heterogeneity contributes to tumor resistance clinical treatment, especially the molecularly targeted therapies such as tyrosine kinase inhibitors (TKIs) androgen receptor signaling (ARSIs). Therapeutic interventions, in turn, induce lineage plasticity (also called infidelity) that also drives therapy resistance. In this Perspective, we focus our discussions on manifested treatment-induced switching epithelial basal/stem-like, mesenchymal, neural lineages. We employ prostate (PCa) prime example highlight ARSI-induced during towards development castration-resistant PCa (CRPC). further discuss how microenvironment (TME) influences therapy-induced plasticity. Finally, offer an updated summary regulators mechanisms driving infidelity, which should be therapeutically extend therapeutic window improve patients' survival.
Language: Английский
Citations
2
Molecular Cancer Research, Journal Year: 2024, Volume and Issue: 23(1), P. 59 - 70
Published: Oct. 17, 2024
Abstract Prostate cancer is a heterogeneous disease with spectrum of pathology and outcomes ranging from indolent to lethal. Although there have been recent advancements in prognostic tissue biomarkers, limitations still exist. We leveraged matrix-assisted laser desorption/ionization imaging formalin-fixed, paraffin embedded prostate specimens determine if N-linked glycans expressed the extracellular matrix lethal neuroendocrine were also conventional adenocarcinomas that associated poor outcomes. found N-glycan fucosylation was abundant as well at time prostatectomy eventually developed recurrent metastatic disease. Analysis patient-derived xenografts revealed this signature enriched differently across organ sites, highest abundance liver metastases. These data suggest fucosylated could be an early biomarker for Implications: studies identify hyper-fucosylated are progress disease, thus advancing discovery providing insights into mechanisms underlying
Language: Английский
Citations
2
JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8
Published: Sept. 30, 2024
PURPOSE The acid phosphatase 1 ( ACP1 ) gene encodes low-molecular-weight protein tyrosine phosphatase, which is overexpressed in prostate cancer (PC) and a potential therapeutic target. We analyzed expression primary/metastatic PC its association with molecular profiles clinical outcomes. METHODS NextGen sequencing of DNA (592-gene/whole-exome sequencing)/RNA(whole-transcriptome sequencing) was performed for 5,028 specimens. -High/ -Low defined as quartile (Q4/1) RNA transcripts per million (TPM). mutational were -quartile-stratified samples. Gene set enrichment analysis used Hallmark collection pathways. PD-L1+(≥2+, ≥5%; SP142) tested by immunohistochemistry. Tumor microenvironment's (TME) immune cell fractions estimated deconvolution/quanTIseq. Overall survival (OS) assessed from initial diagnosis/treatment initiation to death/last follow-up. RESULTS included 3,058 (60.8%) samples the prostate, 634 (12.6%) lymph node metastases (LNMs), 1,307 (26.0%) distant (DMs). higher LNM/DM than (49.8/47.9 v 44.1 TPM; P < .0001). TP53 mutations enriched -Q4 (37.9%[Q4] 27.0%[Q1]; .001) among Pathways associated cycle regulation oxidative phosphorylation -Q4, whereas epithelial-mesenchymal transition tumor necrosis factor-alpha signaling via nuclear factor kappa-light-chain-enhancer activated B-cell pathways -Q1. Neuroendocrine androgen receptor increased -Q4. M2 macrophages natural killer increased, T cells M1 decreased While OS differences between -Q1/Q4 not statistically significant, there trend worse (Q4 Q1: hazard ratio [HR], 1.19 [95% CI, 0.99 1.42]; = .06) DM (HR, 1.12 0.93 1.36]; .22) but LNM 0.98 0.74 1.29]; .87). CONCLUSION ACP1-High tumors exhibit distinct profile cold TME, highlighting 's role pathogenesis novel targeting.
Language: Английский
Citations
1
Revista română de medicină de laborator, Journal Year: 2024, Volume and Issue: 32(3), P. 219 - 228
Published: July 1, 2024
Abstract Background Prostate cancer (PCa) is a common and complex disease in men, often progressing from localized to aggressive meta-static stages requiring advanced therapies. Early detection of PCa relies primarily on multiparametric tests, with limitations, like over-diagnosis lack specificity. Advances molecular profiling, particularly proteomics, could enhance patient stratification personalized Methods We conducted an analysis using Formalin-Fixed Paraffin-Embedded (FFPE) samples 23 patients diagnosed prostatic adenocarcinoma. Proteins were extracted tissues, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The data processed identify proteins subsequent bioinformatics was performed uncover significant pathways potential biomarkers panel. Validation identified carried out through Western blotting (WB). Results Proteomic profiling 1,159 proteins, including 176 significantly elevated tumor tissues. Enrichment highlighted their involvement stress response, protein metabolism, signaling associated progression. Key included mTORC1 signaling, Myc focal adhesion. A biomarker panel consisting KLK3, GDF15, MIF, AZGP1 proposed based discriminatory power distinguishing normal WB confirmed the tumor-specific expression these candidates, GDF15 KLK3. Conclusions present study shows for first time multi-modal approach that combines tissue as new tool patients. offers promise improving tailoring treatment strategies management. Further validation larger cohorts clinical settings warranted establish findings.
Language: Английский
Citations
0
BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)
Published: Nov. 14, 2024
Prostate cancer is the second most common among men worldwide. Mortality highest patients in resource-limited settings (RLS), part due to late-stage disease. Among with metastatic prostate (mPCa), studies have shown significant improvement overall survival use of androgen deprivation therapy (ADT) and taxane-based chemotherapy. However, outcome data treated chemo-endocrine are scarce many settings. The aim this study was determine clinical characteristics 5-year (OS) de novo mPCa at Uganda Cancer Institute (UCI). A retrospective chart review conducted between 2015 2019, histologically confirmed radiological evidence metastasis were reviewed. Sample size estimated for Cox Proportion Hazard regression. Data on laboratory characteristics, survival, predictors extracted. P < 0.05 considered indicate statistical significance. total 300 enrolled over period. median age 68 (IQR 61.5–74) years. At presentation, lower urinary tract symptoms reported nearly all (96.7%, n = 290), specific antigen (PSA) 414.75 ng/ml 40% (n 120) had grade 5 histological scores. In addition receiving ADT, majority (70.3%, 211) received least 6 cycles Overall one year 92.4% (95% CI: 88.6-94.9%), but it declined 45.2% 36.8-53.2%) high Gleason score, presence visceral less than chemotherapy poor outcomes. Patients present histologic grades baseline Specific Antigen levels improved a combination ADT as first-line treatment. We recommend interventions reduce late presentation prospective evaluate treatment efficacy population.
Language: Английский
Citations
0
World Journal of Clinical Cases, Journal Year: 2024, Volume and Issue: 12(27), P. 6070 - 6076
Published: July 29, 2024
BACKGROUND Globally, prostate cancer has become a major threat to men's health, with an increasing incidence and causes serious effects on the quality length of life patients. Despite rapid development medical technology, which provides treatments, including surgery, radiotherapy, endocrine therapy, treatment patients cancer, especially challenge in clinical owing lengthy course treatment, side drugs, impact disease psychological physiological functioning patient, producing poor adherence decline life. AIM To explore nursing intervention prioritizing patient safety case management undergoing therapy. METHODS Eighty who received therapy at our hospital between January 2022 2024 were divided into observation control groups 40 cases per group. The group was treated using routine workflow while guidance safety. Scores for anxiety depression, symptoms, compliance satisfaction compared after three months intervention. RESULTS After intervention, depression scores significantly lower than those (P < 0.05). score, sexual function, hormone function higher CONCLUSION Case based effectively reduced improved their life, compliance, satisfaction.
Language: Английский
Citations
0